Zeus Capital acted as nominated adviser (NOMAD) and sole broker to Oncimmune Holdings plc (Ticker: ONC.L) on its AIM IPO and £11m fundraising
Zeus Capital acted as nominated adviser (NOMAD) and sole broker to Oncimmune Holdings plc (Ticker: ONC.L) on its AIM IPO and £11m fundraising, resulting in a market capitalisation on admission of £66m
Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
Oncimmune is an established company with a pioneering approach to cancer detection. Its methodology has been extensively validated , and over 140,000 of its EarlyCDT-Lung tests have already been sold in the USA. The tests are now part of the 12,000-person ECLS Study being run in collaboration with NHS Scotland in Tayside and Greater Glasgow. This is the largest lung cancer screening trial ever conducted.
Oncimmune was originally spun-out from University of Nottingham in 2002 with facilities in the UK and USA. The funds raised will be used to accelerate the commercial development of the business and to develop early detection tests for Liver and Ovarian cancers.